Overall response rate of 91% in women with locally advanced HER2 negative breast cancer
Two patients reported pathologic complete responses, another patient with clinical complete response
Excellent ongoing durability, with 9 of 10 evaluable patients free of disease progression to date, with up to 40 months of disease-free progression
New study to focus on ER+ breast cancer
Ann: PTX-200 High Overall Response in Ph2a Breast Cancer trial, page-4
-
- There are more pages in this discussion • 106 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PTX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.9¢ |
Change
-0.001(2.50%) |
Mkt cap ! $31.40M | |||
| Open | High | Low | Value | Volume |
| 4.1¢ | 4.1¢ | 3.9¢ | $72.73K | 1.802M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 436541 | 3.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.1¢ | 560576 | 1 |
View Market Depth
| Last trade - 15.59pm 15/11/2024 (20 minute delay) ? |
| PTX (ASX) Chart |